1921
Volume 93, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

An increasing number of immunocompromised individuals are pursuing international travel, and a better understanding of their international travel patterns and pretravel health care is needed. We evaluated the clinical features, itineraries, and pretravel health care of 486 immunocompromised international travelers seen at Global TravEpiNet sites from January 2009 to June 2012. We used bivariate analyses and logistic regressions using random intercept models to compare demographic and travel characteristics, vaccines administered, and medications prescribed for immunocompromised travelers versus 30,702 immunocompetent travelers. Immunocompromised travelers pursued itineraries that were largely similar to those of immunocompetent travelers, with nearly one-third of such travelers visiting countries with low human development indices. Biological agents, including tumor necrosis factor blockers, were commonly used immunosuppressive medications among immunocompromised travelers. A strong collaboration between travel-medicine specialists, primary care doctors, and specialist physicians is needed to prepare immunocompromised people for international travel. Incorporating routine questioning and planning regarding travel into the primary care visits of immunocompromised people may be useful.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0185
2015-11-04
2017-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/5/1110.html?itemId=/content/journals/10.4269/ajtmh.15-0185&mimeType=html&fmt=ahah

References

  1. International Trade Administration. 2013 U.S. Travel and Tourism Statistics. Office of Travel and Tourism Industries, U.S. Department of Commerce. Available at: http://tinet.ita.doc.gov/outreachpages/outbound.general_information.outbound_overview.html. Accessed March 4, 2011.
  2. United Nations World Tourism Organization. Press Release No. PR120020, January 2012. Available at: http://media.unwto.org/en/press-release/2012-01-16/international-tourism-reach-one-billion-2012. Accessed March 5, 2012.
  3. Organ Procurement and Transplantation Network. U.S. transplants performed January–March 2014. Available at: http://optn.transplant.hrsa.gov/data/. Accessed June 24, 2014.
  4. Chen M, Rhodes PH, Hall IH, Kilmarx PH, Branson BM, Valleroy LA, Centers for Disease Control and Prevention (CDC), , 2012. Prevalence of undiagnosed HIV infection among persons aged ≥ 13 years—national HIV surveillance system, United States, 2005–2008. Morb Mortal Wkly Rep 61 (Suppl): 5764.
  5. Uslan DZ, Patel R, Virk A, , 2008. International travel and exposure risks in solid-organ transplant recipients. Transplantation 86: 407412.[Crossref]
  6. Kemper CA, Linett A, Kane C, Deresinski SC, , 1995. Frequency of travel of adults infected with HIV. J Travel Med 2: 8588.[Crossref]
  7. Kemper CA, Linett A, Kane C, Deresinski SC, , 1997. Travels with HIV: the compliance and health of HIV-infected adults who travel. Int J STD AIDS 8: 4449.[Crossref]
  8. Salit IE, Sano M, Boggild AK, Kain KC, , 2005. Travel patterns and risk behaviour of HIV-positive people travelling internationally. CMAJ 172: 884888.[Crossref]
  9. 2011. CDC Health Information for International Travel 2012. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service.
  10. Roukens AH, van Dissel JT, de Fijter JW, Visser LG, , 2007. Health preparations and travel-related morbidity of kidney transplant recipients traveling to developing countries. Clin Transplant 21: 567570.[Crossref]
  11. Wieten RW, Leenstra T, Goorhuis A, van Vugt M, Grobusch MP, , 2012. Health risks of travelers with medical conditions—a retrospective analysis. J Travel Med 19: 104110.[Crossref]
  12. LaRocque RC, Rao SR, Lee J, Ansdell V, Yates JA, Schwartz BS, Knouse M, Cahill J, Hagmann S, Vinetz J, Connor BA, Goad JA, Oladele A, Alvarez S, Stauffer W, Walker P, Kozarsky P, Franco-Paredes C, Dismukes R, Rosen J, Hynes NA, Jacquerioz F, McLellan S, Hale D, Sofarelli T, Schoenfeld D, Marano N, Brunette G, Jentes ES, Yanni E, Sotir MJ, Ryan ET, Global Travel Epinet Consortium; , 2012. Global TravEpiNet: a national consortium of clinics providing care to international travelers—analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009–2011. Clin Infect Dis 54: 455462.[Crossref]
  13. United Nations Development Programme. Human Development Report, 2011. Available at: http://hdr.undp.org/en/content/human-development-report-2011.
  14. Rao SR, LaRocque RC, Jentes ES, Hagmann SHF, Ryan ET, Han PV, Kleinbaum DG, , 2014. Comparison of methods for clustered data analysis in a non-ideal situation: results from an evaluation of predictors of yellow fever vaccine refusal in the Global TravEpiNet (GTEN) consortium. Int J Stat Med Res 3: 215223.[Crossref]
  15. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM, , 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 10981104.[Crossref]
  16. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM, Infectious Diseases Society of America Emerging Infections Network; , 2008. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis 46: 17381740.[Crossref]
  17. Zanger P, Kotter I, Kremsner PG, Gabrysch S, , 2012. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect 18: 670676.[Crossref]
  18. Pena-Sagredo JL, Farinas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibanez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernandez MV, Rodriguez-Gomez M, Maiz O, Lopez R, Cobo T, Pita J, Carmona L, Gonzales-Gay MA, BIOBADASER and EMECAR Groups; , 2009. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy. Clin Exp Rheumatol 27: 920925.
  19. Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podesta E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Lagana B, D Amelio R, , 2010. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 134: 113120.[Crossref]
  20. Kaine JL, Kivitz AJ, Birbara C, Luo AY, , 2007. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 34: 272279.
  21. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I, Infectious Diseases Society of America; , 2014. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58: e44e100.[Crossref]
  22. Orenstein R, , 2005. Travel in patients receiving TNF-alpha inhibitors. Travel Med Infect Dis 3: 105109.[Crossref]
  23. Curtis DJ, Muresan P, Nachman S, Fenton T, Richardson KM, Dominguez T, Flynn PM, Spector SA, Cunningham CK, Bloom A, Weinberg A, , 2015. Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth. PLoS One 10: e0118567.[Crossref]
  24. Berger CT, Greiff V, Mehling M, Fritz S, Meier MA, Hoenger G, Conen A, Recher M, Battegay M, Reddy ST, Hess C, , 2015. Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection. Hum Vaccin Immunother 11: 391396.[Crossref]
  25. George VK, Pallikkuth S, Parmigiani A, Alcaide M, Fischl M, Arheart KL, Pahwa S, , 2015. HIV infection worsens age-associated defects in antibody responses to influenza vaccine. J Infect Dis 211: 19591968.[Crossref]
  26. Centers for Disease Control and Prevention (CDC), 2013. Prevention and control of seasonal influenza with vaccines. recommendations of the Advisory Committee on Immunization Practices—United States, 2013–2014. MMWR Recomm Rep 62: 143.
  27. LaRocque RC, Jentes ES, , 2011. Health recommendations for international travel: a review of the evidence base of travel medicine. Curr Opin Infect Dis 24: 403409.[Crossref]
  28. Mauskopf J, Klesse M, Lee S, Herrera-Taracena G, , 2013. The burden of influenza complications in different high-risk groups: a targeted literature review. J Med Econ 16: 264277.[Crossref]
  29. Centers for Disease Control and Prevention (CDC), 2005. Cruise-ship–associated Legionnaires disease, November 2003–May 2004. Morb Mortal Wkly Rep 54: 11531155.
  30. Wikswo ME, Cortes J, Hall AJ, Vaughan G, Howard C, Gregoricus N, Cramer EH, , 2011. Disease transmission and passenger behaviors during a high morbidity norovirus outbreak on a cruise ship, January 2009. Clin Infect Dis 52: 11161122.[Crossref]
  31. Miller JM, Tam TW, Maloney S, Fukuda K, Cox N, Hockin J, Kertesz D, Klimov A, Cetron M, , 2000. Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect Dis 31: 433438.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0185
Loading
/content/journals/10.4269/ajtmh.15-0185
Loading

Data & Media loading...

  • Received : 08 Mar 2015
  • Accepted : 28 Jun 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error